Research Article

Generalized Portrait of Cancer Metabolic Pathways Inferred from a List of Genes Overexpressed in Cancer

Eugenia Poliakov, David Managadze, and Igor B. Rogozin

1 Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
2 National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA

Correspondence should be addressed to Igor B. Rogozin; rogozin@ncbi.nlm.nih.gov

Received 20 May 2014; Accepted 15 August 2014; Published 27 August 2014

1. Introduction

More than half a century from postulated Warburg theory of cancer cells origin [1], question of changed metabolism in cancer is again taking central place. For several decades a generalized picture of cancer metabolism was replaced by analysis of signaling and oncogenes in each type of cancer. However, now empowered with wealth of knowledge about tumor suppressors, oncogenes, and signaling pathways, reprogramming of cellular metabolism first described as Warburg effect (increased glycolysis to respiration ratio in cancer cells) [2] reemerged as important element of cancer progression [3–5]. The metabolism of one molecule of glucose to two molecules of pyruvate in glycolysis has a net yield of two molecules of ATP. Glycolysis does not require or consume oxygen. Eukaryotic aerobic respiration (oxidative phosphorylation) produces approximately 34 additional molecules of ATP for each glucose molecule. The lower-energy production, per glucose, of anaerobic respiration relative to aerobic respiration, results in greater flux through the pathway under hypoxic (low-oxygen) conditions. It has been hypothesized that, in these cells, glycolytic enzymes associate into a large complex, which results in an increased efficiency of glycolytic flux [6]. Another explanation is based on alternative glycolytic pathway that bypasses ATP production but produces pyruvate [7]. Recent analysis of microarray data across major cancer types showed activation of certain metabolic pathways in cancer cells [8, 9]. These data confirmed that cancer cells upregulate biosynthesis and metabolism of certain nutrients like glycine and glutamine along with upregulated glycolysis [10, 11].

Analysis of cancer molecular signatures deduced from genomics data recently appeared in the literature [12–14]. For example, overexpressed membrane receptors as suggested by an analysis of ESTs (expressed sequences tags) could be used as hallmark of cancer cells [15]. EST datasets were also analyzed by Aouacheria and coworkers to distinguish between normal and tumor tissues [16]. Analysis was done...
in a tissue-specific manner but demonstrated similar patterns of enzymes enrichment in various cancers, for example, glycolytic enzymes, alpha enolase ENO1 (EC 4.2.1.11), pyruvate kinase, muscle PKM2 (EC 2.7.1.40), and glyceraldehyde-3-phosphate dehydrogenase GAPDH (EC 1.2.1.12), were found in three different types of cancer [16]. This result demonstrates that some genes are ubiquitously highly expressed in cancer cells and such genes may be important hallmarks of cancer cells [12].

To analyze level of expression of various proteins including metabolic enzymes across various cancers we used EST data. We also used the NCBI Unigene data across the panel of cancers. We grouped overexpressed enzymes into KEGG pathways and manually analyzed adjacent pathways to analyze enzymatic reactions that take place in cancer cells and to identify major players that are abundant in cancer protein machinery.

### 2. Materials and Methods

The 23,586 nonredundant coding sequences (CDS) of human genes from the human genome draft build 35, the April 2012 freeze, obtained at the NCBI ftp server were used as reference sequences to be compared with the EST sequences. The EST sequences were from the dbEST release of June 2012. Each EST library was assigned to either cancer-related (1,437 libraries; 1,848,538 ESTs (26%)) or normal tissue (7,309 libraries; 5,276,385 ESTs (74%)) bins (the file EST_libraries.xls is available at ftp://ftp.ncbi.nlm.nih.gov/pub/managdav/paper_suppl/est_cancer_pathways/). The CDS set was searched against dbEST using the BLASTN program with the default parameters. The number of ESTs with at least 97% identity and alignment length of at least 200 nucleotides or longer was counted. The Unigene database was used to verify results of BLASTN-dbEST searches.

We used two statistical filters to delineate a set of genes overexpressed in cancer (10 genes with the largest number of cancer EST libraries are shown in the Table 1).

1. We included a gene in a list of preliminarily candidates if the number of cancer ESTs is greater in comparison with normal ESTs using Fisher $\chi^2$ exact test ($X_1 - X_2, X_2, X_3 - X_4, X_4$) (an arbitrary threshold $P$ value $= 0.01$). $X_1$ is the total number of cancer ESTs, $X_2$ is the number of cancer ESTs for a given gene, $X_3$ is the total number of normal ESTs for a given gene, and $X_4$ is the number of normal ESTs for a given gene.

2. We accepted a gene in the final list (Supplementary Table S1; Supplementary Material available online at http://dx.doi.org/10.1155/2014/646193) from the preliminarily candidates if the number of cancer ESTs per EST library is greater in comparison with normal ESTs per EST library using Fisher $\chi^2$ exact test ($X_1, X_2, X_3, X_4$) (an arbitrary threshold $P$ value $= 0.01$). $X_1$ is the total number of cancer ESTs for a given gene, $X_2$ is the number of cancer EST libraries with at least one BLASTN hit for a given gene, $X_3$ is the total number of normal ESTs for a given gene, and $X_4$ is the number of normal EST libraries with at least one BLASTN hit for a given gene. In other words, if a gene has an EST-detected expression level in an EST library, it should be expressed in cancer EST libraries higher than in normal EST libraries.

A KEGG pathway enrichment in genes overexpressed in cancer libraries (Table 2) was estimated using the Fisher $\chi^2$ exact test ($X_1$-$X_2, X_2, X_3$-$X_4, X_4$) and the KEGG database [17]. $X_1$ is the total number of proteins in the initial set, $X_2$ is the number of proteins in a given pathway, $X_3$ is the total number of genes that are overexpressed in cancer, $X_4$

---

**Table 1: Examples of genes overexpressed in cancer: ten genes with the largest number of EST libraries.**

| Gene   | Number of cancer ESTs | Number of cancer EST libraries | Number of normal ESTs | Number of normal EST libraries | Gene description                                      |
|--------|------------------------|-------------------------------|-----------------------|-------------------------------|-------------------------------------------------------|
| EEF1A1 | 26747                  | 380                           | 54872                 | 1436                          | Translation elongation factor                          |
| GAPDH  | 11388                  | 300                           | 9446                  | 858                           | Glyceraldehyde-3-phosphate dehydrogenase              |
| ACTG1  | 9831                   | 295                           | 8826                  | 879                           | Actin gamma                                           |
| FTH1   | 5264                   | 260                           | 6627                  | 758                           | Ferritin, heavy polypeptide 1                         |
| EEF1G  | 6575                   | 255                           | 7185                  | 783                           | Eukaryotic translation elongation factor 1 gamma       |
| RPLP0  | 6583                   | 253                           | 6400                  | 683                           | Ribosomal protein, large subunit, P0                   |
| HSP90AB1| 4035                  | 253                           | 7178                  | 801                           | Heat shock protein 90 kDa alpha (cytosolic), class B member 1 |
| PKM2   | 4794                   | 248                           | 7593                  | 760                           | Pyruvate kinase, muscle                               |
| FTL    | 4495                   | 246                           | 7784                  | 599                           | Ferritin, light polypeptide                            |
| RPL3   | 6278                   | 242                           | 7463                  | 753                           | Ribosomal protein L3                                   |

The complete list of genes overexpressed in cancer is shown in Supplementary Table S1 (also available at ftp://ftp.ncbi.nlm.nih.gov/pub/managdav/paper_suppl/est_cancer_pathways/).
Table 2: KEGG metabolic pathways enriched in genes that are overexpressed in cancer.

| Pathway                                      | Number of genes in a pathway (X2) | Number of genes overexpressed in cancer (X4) | Pathway enrichment |
|----------------------------------------------|-----------------------------------|----------------------------------------------|--------------------|
| Glycolysis/gluconeogenesis                   | 62                                | 10                                           | $2.8 \times 10^{-7}$ |
| Oxidative phosphorylation                    | 135                               | 10                                           | 0.00015            |
| Pyruvate metabolism                          | 40                                | 5                                            | 0.00083            |
| Metabolism of xenobiotics by cytochrome P450 | 70                                | 6                                            | 0.0016             |
| Fructose and mannose metabolism              | 34                                | 4                                            | 0.0034             |
| One carbon pool by folate                    | 17                                | 3                                            | 0.0041             |
| TCA cycle (citrate cycle)                    | 32                                | 3                                            | 0.02               |
| Glycerolipid metabolism                      | 49                                | 3                                            | 0.054              |
| Steroid hormone biosynthesis                 | 55                                | 3                                            | 0.07               |
| Pentose phosphate pathway                    | 27                                | 2                                            | 0.082              |
| Purine metabolism/purine de novo biosynthesis| 159                               | 4                                            | 0.35               |
| Pyrimidine metabolism/pyrimidine de novo biosynthesis | 98   | 3                                            | 0.23               |
| Cysteine and methionine metabolism           | 34                                | 2                                            | 0.12               |
| Aminoacyl tRNA biosynthesis                  | 41                                | 2                                            | 0.16               |
| Fatty acid metabolism                        | 43                                | 2                                            | 0.17               |
| N-Glycan biosynthesis                        | 46                                | 2                                            | 0.19               |
| Phenylalanine/tyrosine/histidine metabolism  | 18/42/29                          | 3                                            | —                  |
| Enzymes introducing posttranslational       | ?                                 | 6                                            | —                  |
| modifications                                 |                                   |                                              |                    |
| Additional antioxidant systems                | ?                                 | 3                                            | —                  |

Pathway enrichment is estimated using the Fisher $2 \times 2$ exact test ($X_1 \times X_2$, $X_2 \times X_3 \times X_4$, $X_4$). $X_1$ is the total number of genes in the initial set (23,586 genes), $X_2$ is the number of proteins in a given pathway, $X_3$ is the total number of genes that are overexpressed in cancer (394 genes), and $X_4$ is the total number of genes in a given pathway that are overexpressed in cancer.

3. Results

3.1. Analysis of Genes/Pathways Overexpressed in Cancer. We analyzed large collections of EST libraries associated with cancer and compared them to EST libraries from normal tissues. We tried to select genes that are highly expressed in cancer and the level of expression is substantially different between cancer and normal samples taking into account that EST data is inherently semiquantitative. We used two statistical filters to delineate a list of genes that are highly expressed in many cancer-associated EST libraries (see Section 2). In this way we attempted to remove genes that are associated with specific types of cancer in order to reconstruct a generalized portrait of a cancer cell. We delineated 394 genes that are overexpressed in cancer cells according to statistical filters (see Section 2, Supplementary Table S1; the file Supp_table_S1.xls is also available at ftp://ftp.ncbi.nlm.nih.gov/pub/manager/paper_supp/est_cancer_pathways/). A wide variety of functional themes were found in this list and many products of these genes are proteins involved in translation. For example, among 10 genes with the largest number of cancer-related EST libraries, two ribosomal proteins and two translation elongation factors were found (Table 1). This is consistent with many previous observations of highly significant elevation of protein synthesis rates and the expression of several translation components in various cancer cells indicating an importance of ribosome function and translational control in tumor progression [18–21].

We used the KEGG database [17] to assign proteins overexpressed in cancer to various metabolic pathways. We found several KEGG pathways that are significantly enriched in proteins overexpressed in cancer whereas many other pathways do not show a significant enrichment in genes overexpressed in cancer although they contain two or more genes overexpressed in cancer (Table 2). We discuss all these pathways below in more detail.

3.2. Glycolysis/Gluconeogenesis. Ten enzymes (TPI1, PGAM1, ENO1, PKM2, ALDH3A1, GAPDH, LDHB, ALDH3B1,
3.3. Oxidative Phosphorylation. Ten enzymes (ATP5F1, SDHD, ATP5B, UQCRCI, NDUF7, ATP6V0E1, NDUF9, NDUF5, and CYC) out of 135 proteins participating in this pathway were overexpressed in cancer (Table 2 and Supplementary Table S1). It was demonstrated that hypoxic cancer cells maintain active, though diminished, oxidative phosphorylation even at 1% oxygen. ATP production in these cells is around 40% of ATP production under normal oxygen conditions and their results suggest that, under hypoxia, the autophagy is required to support ATP production [24]. Our data demonstrate that the oxidative phosphorylation is important for cancer survival and growth. Overexpression of LDHB according to cancer EST analysis (Supplementary Table S1) is also pointing to a possible utilization of lactate for the oxidative metabolism [25, 26].

3.4. Pyruvate Metabolism. Pyruvate is produced in glycolysis and is used for lactate production. High ratio of lactate/pyruvate is used for metabolic imaging of prostate cancer [27]. Lactate is a prominent substrate that fuels the oxidative metabolism of oxygenated tumor cells. There is a symbiosis in which glycolytic and oxidative tumor cells mutually regulate their access to energy metabolites [25]. Preferential utilization of lactate for oxidative metabolism spares glucose that may in turn reach hypoxic tumor cells [26]. Five enzymes (LDHB, MDH2, PKM2, AKRIB1, and AKRIB10) out of 40 enzymes in pyruvate metabolism pathway are overexpressed in cancer (Table 2 and Supplementary Table S1). Surprisingly, we found an overexpression of the lactate dehydrogenase B enzyme in certain cancers (Supplementary Table S1) and no significant upregulation of the lactate dehydrogenase A enzyme that has been suggested to have a ubiquitous role in tumor metabolism and growth [28].

3.5. Metabolism of Aldehydes (Xenobiotics, Drugs) by Cytochrome P450. We found that our EST dataset is enriched in various aldehyde dehydrogenases (ALDH3A1, ALDH3B1, and ALDH3B2) (Table 2 and Supplementary Table S1). Aldehyde dehydrogenase superfamily plays an important role in the enzymatic detoxification of endogenous and exogenous aldehydes and in the formation of molecules that are important in cellular processes. Additionally, ALDH3B1 expression is upregulated in many human tumors and this enzyme is catalytically active toward aldehydes derived from lipid peroxidation, suggesting a potential role against oxidative stress [29]. Moreover, three members of aldo-keto reductases (AKRs), AKR1C1, AKR1C2, and AKR1C3, are overexpressed in cancer (Table 2 and Supplementary Table S1). The resistance towards the chemotherapeutic drug cisplatin in colon cancers is believed to be a result of decreased sensitivity toward cellular damages evoked by oxidative-stress-derived aldehydes, 4-hydroxy-2-nonenal and 4-oxo-2-nonenal, that are detoxified by AKR1C1 and AKR1C3 [30]. Metabolism of xenobiotics by cytochrome P450 pathway has six overexpressed enzymes from total 70 enzymes. Furthermore, one member of the superfamily of short-chain dehydrogenases/reductases (SDR) was found to be overexpressed in cancer (DHRS2 or Hep27, Supplementary Table S1), SDR catalyzes the NADPH-dependent reduction of dicarbonyl compounds [31].

3.6. Fructose and Mannose Metabolism. Fructose provides an alternative carbon source for glycolysis, entering downstream of glucose and bypassing two key rate-limiting steps. Whereas glucose favors overall growth kinetics, fructose enhances protein and nucleotide synthesis and appears to promote a more aggressive cancer phenotype [32, 33]. Four enzymes (TPI1, AKRIB10, ALDOA, and AKRIB1) out of 34 enzymes in this pathway are overexpressed in cancer (Table 2 and Supplementary Table S1). All these enzymes participate in a variety of metabolic pathways.

3.7. One Carbon Pool by Folate. Three enzymes (MTHFD2, ATIC, and SHMT2) in this pathway were found to be overexpressed in many cancers (Table 2). This result suggests that most of tetrahydrofolate (THF) forms (5,6,7,8-THF; 10-formyl-THF; 5,10-methyl-THF; 5,10-methylene-THF) are synthesized in cancer cells. Byproduct of serine hydroxymethyltransferase 2 (SHMT2) is glycine and its biosynthesis and metabolism is upregulated in proliferating cancer cells [11]. The 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), which synthesizes L-methionine and THF from L-homocysteine and 5-methyltetrahydrofolate, was not included in our list (Supplementary Table S1). However, the MTR cofactor vitamin B12 (cobalamin) ATP transporter MMADHC is overexpressed in cancer (Supplementary Table S1).

3.8. TCA Cycle (Citrate Cycle). Three enzymes (FH, SDHD, and MDH2) were found to be overexpressed in the TCA cycle (32 enzymes, Table 2 and Supplementary Table S1). Even though mutations in FH and SDHD lead to development of tumors [34], overexpression of these three enzymes is likely to lead to accumulation of oxaloacetate. TCA cycle is subject to metabolic reprogramming in cancer cells [35, 36]. In the transformed cells, the tricarboxylic acid (TCA) cycle was active but was characterized by an efflux of substrates for use in biosynthetic pathways, particularly fatty acid synthesis. Glutamine metabolism in these cells supports restoration of oxaloacetate for continued TCA cycle function as well as NADPH production [37]. We found in our list of genes (Supplementary Table S1) the glutamine transporter SLC1A5 that is important for survival of lung cancer cells [38].

3.9. Glycerolipid Metabolism. We observed overexpression of monoglyceride lipase (MGLL) that catalyzes the conversion of monoacylglycerides to free fatty acids and glycerol. Expression of this gene may play a role in tumorigenesis and metastasis. Also aldo-keto reductases AKRIB1 and
AKRIB10 enriched in cancer ESTs catalyze reduction of D-glyceraldehyde to glycerol and 2-hydroxypropanal to propane-1,2-diol in glycerolipid metabolism. A total of three enzymes out of 49 enzymes in this pathway are overexpressed in cancer although the pathway enrichment is not significant (Table 2 and Supplementary Table S1).

3.10. Steroid Hormone Biosynthesis. The same three members of AKRs (AKR1C1, AKR1C2, and AKR1C3) that are involved in metabolism of aldehydes (xenobiotics, drugs) by cytochrome P450 and are overexpressed in cancer (see above) participate in the steroid biosynthesis pathway and could play more than detoxifying role in cancer cells. Only these three enzymes are present in our list among 55 enzymes in this pathway (Table 2).

3.11. Pentose Phosphate Pathway. Two enzymes (ALDOA, PGD) from pentose phosphate pathway (27 genes) are overexpressed in cancer (Table 2 and Supplementary Table S1). This pathway is adjacent to glycolysis pathway and feeds into purine and pyrimidine metabolism producing 5-phospho-α-D-ribose 1-pyrophosphate (PRPP).

3.12. Purine Metabolism/Purine De Novo Biosynthesis. The de novo synthesis of the purine ring is mostly required in cells when DNA replication occurs and the activity of the metabolic pathway in most of tissues is relatively low [39]. Differentiated cells largely employ the salvage pathway, which recycle nucleotides by retrieving the purine ring after nucleic acid or coenzyme breakdown [39].

Four enzymes in the purine metabolism/purine de novo biosynthesis KEGG pathway are overexpressed in cancer (Table 2 and Supplementary Table S1). ATIC encodes a bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway. ATIC inhibitors are being developed as anticancer therapy [40, 41]. IMPDH2 encodes the rate-limiting enzyme in the de novo guanine nucleotide biosynthesis. These two enzymes are key enzymes in the de novo synthesis of purine nucleotides. The other two enzymes involved in this pathway are not exclusive for this pathway. PKM2 catalyzes the transfer of a phosphohydride group from phosphoenolpyruvate to ADP (GDP), generating ATP (GTP) and pyruvate. The DNA polymerase delta subunit 2 (POLD2) is involved in DNA synthesis and repair [42].

3.13. Pyrimidine Metabolism/Pyrimidine De Novo Biosynthesis. Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) enzyme catalyzing the first three steps in the 6-step pathway of pyrimidine de novo biosynthesis are overexpressed in cancer (Supplementary Table S1). Additionally, the uridine phosphorylase 1 (UPP1) participates in degradation and salvage of pyrimidine ribonucleosides. The DNA polymerase delta subunit 2 (POLD2) incorporates pyrimidine and purine nucleotides in DNA. Three enzymes in this KEGG pathway (98 genes) are overexpressed in cancer (Table 2 and Supplementary Table S1).

3.14. Cysteine and Methionine Metabolism. Adenosylhomocysteinase (AHCY) enzyme that produces L-homocysteine and adenosine by hydrolysis of S-adenosyl-L-homocysteine was found to be overexpressed in cancer (Table 2). This protein is in cysteine and methionine metabolism pathway and also may be used by the MTR enzyme in the one carbon pool by folate pathway (see above). LDHB is another enzyme in the pathway that is overexpressed in cancer (Supplementary Table S1).

3.15. Aminoacyl tRNA Biosynthesis. The cytoplasmic methionyl-tRNA synthetase (MARS) and the cytoplasmic alanyltRNA synthetase (AARS) enzymes that charge tRNAs with their cognate amino acids were found to be overexpressed in cancer (Table 2 and Supplementary Table S1).

3.16. Fatty Acid Metabolism. Two enzymes that participate in the fatty acid metabolism are overexpressed in cancer. The mitochondrial enoyl-CoA hydratase, short chain 1 (ECHS1) catalyzes the second step of the mitochondrial fatty acid beta-oxidation pathway. Second enzyme is the stearoyl-CoA desaturase (delta-9-desaturase) (SCD), which is involved in synthesis of monounsaturated fatty acids, mostly the oleic acid. Recently, it has been shown that cancer survival is dependent on unsaturated fatty acids and is implicated SCD in this process [43]. Additionally, SCD inhibition causes cancer cell death by depleting monounsaturated fatty acids [44]. We also found that the fatty acid transporter SCP2, which protects fatty acids from oxidation, is overexpressed in cancer. SCD expression is upregulated by retinoic acid in various untransformed cell lines [45]. In our EST database we see an overexpression of cellular retinoic acid binding protein 2 (CRABP2) together with MYCN proteins that have been shown to be upregulated and correlated in variety of cancers [46]. Aldo-keto reductases overexpressed in our cancer dataset (AKR1C1, AKR1B10, and AKR1C3) are involved in the reduction of retinal to retinol (Table 2 and Supplementary Table S1).

3.17. N-Glycan Biosynthesis. Glycosylation is one of the most common posttranslational modification reactions and changes in oligosaccharide structures are associated with many physiological and pathological events, including cell growth, migration, differentiation, and tumor invasion [47]. N-Glycans are involved in cancer progression and MGAT4 mainly participate in branching of N-glycans [48]. Number of Mgt4b transcripts increased considerably in diethylnitrosamine-induced hepatocellular carcinoma mice [49]. DPM1 is enzyme that forms dolichol phosphate mannosyltransferase (Dol-P-Man), which is the mannose donor in pathways leading to N-glycosylation and O-mannosylation. We found these two enzymes to be overexpressed in cancer (2 out of 46 enzymes in this pathway). One enzyme (farnesyl diphosphate synthase FDPS) from the terpenoid biosynthesis pathway (1 out of 15 enzymes) that feeds in N-glycan biosynthesis pathway was also overexpressed in cancer (Table 2 and Supplementary Table S1).

3.18. Phenylalanine/Tyrosine/Histidine Metabolism. Three enzymes (ALDH3B1, ALDH3B2, and ALDH3A1) that
participate in the oxidation of acetaldehyde to acetate in the glycolysis/gluconeogenesis pathway and are involved in xenobiotics and drug oxidation by cytochrome P450 also participate in metabolism of amino acids phenylalanine (18 enzymes), tyrosine (42 enzymes), and histidine (29 enzymes) (Table 2 and Supplementary Table S1). We did not attempt to analyze enrichment of phenylalanine/tyrosine/histidine metabolism due to the obvious overlap with the glycolysis/gluconeogenesis pathway that is highly enriched in cancer-associated genes (Table 2).

3.19. Enzymes Introducing Posttranslational Modifications. Introduction of disulfide bonds by Cys mutations has been shown to improve the physical stability of some proteins [50]. We observed that three disulfide isomerases, AGR2, AGR3, and TXNDC5, are overexpressed in cancer (Table 2). AGR2 is the prouoncogenic protein that could be used as a tumor biomarker [51]. AGR3 is overexpressed by a hormone-(estrogen-receptor α-) independent mechanism and identifies a novel protein-folding associated pathway that could mediate resistance to DNA-damaging agents in human cancers [52].

We also observed that one atypical excreted disulfide oxidase quiescin sulphydryl oxidase 1 (QSOX1), which supports cell-matrix adhesion and cell migration [53], is markedly overexpressed in cancer (Supplementary Table S1).

Third class of protein modifying enzymes we observed in our dataset (Supplementary Table S1) is peptidyl-prolyl isomerases (PPIA) that are known to accelerate protein folding. PPIA is one member we found in our list (Supplementary Table S1). Another member is the peptidyl-prolyl isomerase FKBP4 that is a cochaperone which activates RNA interference-mediated silencing in mammalian cells [54, 55].

3.20. Additional Antioxidant Systems. Our list of genes overexpressed in cancer is also enriched in certain antioxidant enzymes (peroxiredoxins 1 and 3 (PRXD1 and PRXD3) and cytochrome b561 (CYB561)) (Supplementary Table S1). Peroxiredoxins reduce hydrogen peroxide and alkyl hydroperoxides and CYB561 is involved in a reduction of ascorbate radicals.

4. Discussion

The use of EST to measure gene expression requires a lot of caution because many libraries may have insufficient coverage of low and moderately expressed genes. It should be noted that EST-based expression analyses were used in several studies of cancer cells [15, 16]. We assume that cancer ESTs are a good tool to study general properties of gene highly expressed in cancer cells because the statistics were collected over a large number of EST libraries that compensate to some extent a semiquantitative nature of any EST-based expression measure. We have no doubt that when RNAseq data will be available for a range of libraries/tissues similar to dbEST, this will substantially improve the generalized portrait of cancer metabolic pathways.

There are many computational approaches for analysis of metabolic and signaling pathway enrichment [56]. We used the simplest approach in this paper: the Fisher exact test (Table 2). The DAVID system [57] uses a more conservative implementation of this test. We analyzed the dataset using the DAVID system and found a very similar list of metabolic pathways although only three pathways were significantly enriched in genes that were found to be overexpressed in cancer (Supplementary Table S1): glycolysis/gluconeogenesis (EASE Score = 1.2 × 10⁻⁴), oxidative phosphorylation (EASE Score = 2.6 × 10⁻²), and metabolism of xenobiotics by cytochrome P450 (EASE Score = 4.5 × 10⁻²). We do not see this as a contradiction with our results (Table 2) and differences in P values are likely to reflect known methodological problems with the analysis of pathway enrichment [56]. We also observed obvious problems with some KEGG pathways: for example, for the purine metabolism, the de novo purine biosynthesis pathway and the salvage pathway are merged into one KEGG pathway (Table 2). However it was shown that only de novo purine biosynthesis is overexpressed in cancer cells [40, 41]. The same problem was found for the pyrimidine metabolism (Table 2). Therefore the insignificant P values for the pathway enrichment (Table 2) do not necessarily indicate that such pathways are not important for cancer initiation and progression.

There are numerous attempts to build a census of human cancer genes [12–14, 58, 59]; for example, Futreal et al. [58] and Santarius et al. [12] identified ~400 candidate cancer-related genes. An important direction along this venue of research is development of predictive models for cancer-associated genes that could accelerate their identification. Such models have been developed for specific types of cancer. One example of such studies is a complex statistical model for the prediction of prostate cancer genes [60]. In our study we applied a complementary approach using simplified statistical filters for prediction of genes that are overexpressed in all available cancer EST libraries without classifying them into types and subtypes (Table 1 and Supplementary Table S1). In other words, we tried to delineate a list of broadly overexpressed genes and a generalized portrait of cancer metabolic pathways that are expected to be overrepresented in this list. Another important difference is that in this list we do not expect that genes involved in metabolic pathways have many somatic nonsynonymous mutations that are likely to cause inactivation or gain of a new function; an excess of such mutations has been used in previous attempts to build a census human cancer genes [12–14, 58, 59]. Genes that are found in many cancer EST libraries (Supplementary Table S1) should be marked (or even removed) as nonspecific cancer-associated genes when researchers analyze genes overexpressed in certain types of cancer. On the other hand, we know that cancer modifies normal metabolic processes to fulfill its high growth and energy demands and the above described metabolic pathways seem to be universally central for cancerous growth and progression. Enzymes that are highly expressed in cancer along these metabolic pathways could provide multiple targets for desirable inhibition of cancer progression.
Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Mikhail Galperin, Youri Pavlov, Svetlana Shabalina, and Eugene Koonin for useful discussions. This work was supported by the National Institutes of Health Intramural Research Program of the National Eye Institute and the Intramural Research Program of the National Library of Medicine at the National Institutes of Health (US Department of Health and Human Services).

References

[1] O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956.
[2] O. Warburg, F. Wind, and E. Negelein, “The metabolism of tumors in the body,” The Journal of General Physiology, vol. 8, no. 6, pp. 519–530, 1927.
[3] L. Jiang and R. J. Deberardinis, “Cancer metabolism: when more is less,” Nature, vol. 492, no. 7429, pp. 362–363, 2012.
[4] L. Tasselli and K. F. Chu, “Cancer: metabolism in ‘the driver’s seat,” Nature, vol. 492, no. 7429, pp. 356–362, 2012.
[5] M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the warburg effect: the metabolic requirements of cell proliferation,” Science, vol. 324, no. 5930, pp. 1029–1033, 2009.
[6] W. Kowalski, D. Nocon, A. Gamian, J. Kolodziej, and D. Rakus, “Association of C-terminal region of phosphoglycerate mutase with glycolytic complex regulates energy production in cancer cells,” Journal of Cellular Physiology, vol. 227, no. 6, pp. 2613–2621, 2012.
[7] M. G. V. Heiden, J. W. Locasale, K. D. Swanson et al., “Evidence for an alternative glycolytic pathway in rapidly proliferating cells,” Science, vol. 329, no. 5998, pp. 1492–1499, 2010.
[8] M. G. H. Chun and R. J. Shaw, “Cancer metabolism in breadth and depth,” Nature Biotechnology, vol. 31, no. 6, pp. 505–507, 2013.
[9] J. Hu, J. W. Locasale, J. H. Bielas et al., “Heterogeneity of tumor-induced gene expression changes in the human metabolic network,” Nature Biotechnology, vol. 31, no. 6, pp. 522–529, 2013.
[10] J. Son, C. A. Lyssiotis, H. Ying et al., “Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway,” Nature, vol. 496, no. 7443, pp. 101–105, 2013.
[11] M. Jain, R. Nilsson, S. Sharma et al., “Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation,” Science, vol. 336, no. 6084, pp. 1040–1044, 2012.
[12] T. Santarius, J. Shipley, D. Brewer, M. R. Stratton, and C. S. Cooper, “A census of amplified and overexpressed human cancer genes,” Nature Reviews Cancer, vol. 10, no. 1, pp. 59–64, 2010.
[13] E. Wang, “Understanding genomic alterations in cancer genomes using an integrative network approach,” Cancer Letters, vol. 340, no. 2, pp. 261–269, 2013.
[14] E. Wang, N. Zaman, S. McGee, J. S. Milanese, A. Masoudi-Nejad, and M. O’Connor-McCourt, “Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data,” Seminars in Cancer Biology, 2014.
[15] K. R. Kampen, “Membrane proteins: the key players of a cancer cell,” Journal of Membrane Biology, vol. 242, no. 2, pp. 69–74, 2011.
[16] A. Aouacheria, V. Navratil, A. Barthelaxa, D. Mouchiroud, and C. Gautier, “Bioinformatic screening of human ESTs for differentially expressed genes in normal and tumor tissues,” BMC Genomics, vol. 7, article 94, 2006.
[17] M. Kanehisa, S. Goto, M. Kawashima, M. Furumichi, and M. Tanabe, “Data, information, knowledge and principle: back to metabolism in KEGG,” Nucleic Acids Research, vol. 42, Database issue, pp. D199–D205, 2014.
[18] N. Konodoh, M. Shuda, K. Tanaka, T. Wakatsuki, A. Hada, and M. Yamanoto, “Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma,” Anticancer Research, vol. 21, no. 4, pp. 2429–2433, 2001.
[19] M. Stoneley and A. E. Willis, “Abortive regulation of translation initiation in tumorigenesis,” Current Molecular Medicine, vol. 3, no. 7, pp. 597–603, 2003.
[20] M. J. Clemens, “Targets and mechanisms for the regulation of translation in malignant transformation,” Oncogene, vol. 23, no. 18, pp. 3180–3188, 2004.
[21] M. Lai and J. Xu, “Ribosomal proteins and colorectal cancer,” Current Genomics, vol. 8, no. 1, pp. 43–49, 2007.
[22] H. R. Christofk, M. G. Vader Heiden, M. H. Harris et al., “The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth,” Nature, vol. 452, no. 7184, pp. 230–233, 2008.
[23] S. Mazurek, C. B. Boschek, F. Hugo, and E. Eigenbrodt, “Pyruvate kinase type M2 and its role in tumor growth and spreading,” Seminars in Cancer Biology, vol. 15, no. 4, pp. 300–308, 2005.
[24] C. Frezza, L. Zheng, D. A. Tennant et al., “Metabolic profiling of hypoxic cells revealed a catalytic signature required for cell survival,” PloS ONE, vol. 6, no. 9, Article ID e24411, 2011.
[25] P. Souveaux, F. Végran, T. Schroeder et al., “Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice,” Journal of Clinical Investigation, vol. 118, no. 12, pp. 3930–3942, 2008.
[26] O. Feron, “Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells,” Radiotherapy and Oncology, vol. 92, no. 3, pp. 329–333, 2009.
[27] S. J. Nelson, J. Kurbanezic, D. B. Vigneron et al., “Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate,” Science Translational Medicine, vol. 5, no. 198, Article ID 198ra108, 2013.
[28] M. L. McCleland, A. S. Adler, Y. Shang et al., “An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer,” Cancer Research, vol. 72, no. 22, pp. 5812–5823, 2012.
[29] S. A. Marchitti, D. J. Orrlick, C. Brocker, and V. Vasiliou, “Aldehyde dehydrogenase 3B1 (ALDH3B1): immunohistochemical tissue distribution and cellular-specific localization in normal and cancerous human tissues,” Journal of Histochemistry & Cytochemistry, vol. 58, no. 9, pp. 765–783, 2010.
[30] T. Matsunaga, A. Hojo, Y. Yamane, S. Endo, O. El-Kabbani, and A. Hara, “Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers,” Chemico-Biological Interactions, vol. 202, no. 1–3, pp. 234–242, 2013.
N. Shaqfet, J. Shaqfet, G. Eissner et al., "Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarboxyl reductase expressed in vascular endothelial tissue," Cellular and Molecular Life Sciences, vol. 63, no. 10, pp. 1205–1213, 2006.

H. Liu, D. Huang, D. L. McArthur, L. G. Boros, N. Nissen, and A. P. Heaney, "Fructose induces transketolase flux to promote pancreatic cancer growth," Cancer Research, vol. 70, no. 15, pp. 6368–6376, 2010.

A. M. Port, M. R. Ruth, and N. W. Istfan, "Fructose consumption and cancer: is there a connection?" Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 5, pp. 367–374, 2012.

B. E. Baysal, R. E. Ferrell, J. E. Willett-Brozick et al., "Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma," Science, vol. 287, no. 5454, pp. 848–851, 2000.

A. Schulze and A. L. Harris, "How cancer metabolism is tuned for proliferation and vulnerable to disruption," Nature, vol. 491, no. 7424, pp. 364–373, 2012.

N. Raimundo, B. E. Baysal, and G. S. Shadel, "Revisiting the TCA cycle: signaling to tumor formation," Trends in Molecular Medicine, vol. 17, no. 11, pp. 641–649, 2011.

R. J. DeBerardinis, A. Mancuso, E. Daikhin et al., "Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19345–19350, 2007.

M. Hassanin, M. D. Hoeksema, M. Shiota et al., "SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival," Clinical Cancer Research, vol. 19, no. 3, pp. 560–570, 2013.

P. M. C. Smith and C. A. Atkins, "Purine biosynthesis. Big in cell division, even bigger in nitrogen assimilation," Plant Physiology, vol. 128, no. 3, pp. 793–802, 2002.

A. C. Racanelli, S. B. Rothbart, C. L. Heyer, and R. G. Moran, "Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition," Cancer Research, vol. 69, no. 13, pp. 5467–5474, 2009.

I. B. Spurr, C. N. Brits, F. Cuda, S. J. Benkovic, J. P. Blaydes, and A. Tavassoli, "Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization," ChemBioChem, vol. 13, no. 11, pp. 1628–1634, 2012.

Y. I. Pavlov, P. V. Shcherbakova, and I. B. Rogozin, "Roles of DNA polymerases in replication, repair, and recombination in eukaryotes," International Review of Cytology, vol. 255, pp. 41–132, 2006.

U. V. Roontang, J. G. Pabalan, X. Wang et al., "Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy," Molecular Cancer Research, vol. 9, no. 11, pp. 1551–1561, 2011.

P. Mason, B. Liang, L. Li et al., "SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids," PLoS ONE, vol. 7, no. 3, Article ID e38823, 2012.

R. A. Igal, "Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer," Carcinogenesis, vol. 31, no. 9, pp. 1509–1515, 2010.

A. Gupta, P. Kessler, J. Rawwas, and B. R. G. Williams, "Regulation of CRABP-II expression by Myc/N in Wilms tumor," Experimental Cell Research, vol. 314, no. 20, pp. 3663–3668, 2008.

Y. Zhao, M. Takahashi, J. Gu et al., "Functional roles of N-glycans in cell signaling and cell adhesion in cancer," Cancer Science, vol. 99, no. 7, pp. 1304–1310, 2008.

K. S. Lau and J. W. Dennis, "N-Glycans in cancer progression," Glycobiology, vol. 18, no. 10, pp. 750–760, 2008.

B. Blomme, F. Heindryckx, J. M. Stassen, A. Geerts, I. Colle, and H. Van Vlierberghe, "Serum protein N-glycan alterations of diethylamino-salicylate-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor," Molecular and Cellular Biochemistry, vol. 372, no. 1-2, pp. 199–210, 2013.

M. V. Trivedi, J. S. Laurenc, and T. J. Siahaan, "The role of thiols and disulfides on protein stability," Current Protein and Peptide Science, vol. 10, no. 6, pp. 614–625, 2009.

E. Chevet, D. Fessart, F. Delom et al., "Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development," Oncogene, vol. 32, no. 20, pp. 2499–2509, 2013.

T. A. Gray, N. J. MacLaine, C. O. Michie et al., "Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models," Journal of Immunological Methods, vol. 378, no. 1-2, pp. 20–32, 2012.

T. Ilani, A. Alon, I. Grossman et al., "A secreted disulfide catalytic controls extracellular matrix composition and function," Science, vol. 341, no. 6141, pp. 74–76, 2013.

J. M. Pare, P. LaPointe, and T. C. Hobman, "Hsp90 cochaperones p23 and FKBP4 physically interact with hAgo2 and activate RNA interference-mediated silencing in mammalian cells," Molecular Biology of the Cell, vol. 24, no. 15, pp. 2303–2310, 2013.

N. J. Martinez, H. M. Chang, R. Borrajo Jde, and R. I. Gregory, "The co-chaperones Fkbp4/5 control Argonaute2 expression and facilitate RISC assembly," RNA, vol. 19, pp. 1583–1593, 2013.

P. Khatri, M. Sirola, and A. J. Butte, "Ten years of pathway analysis: current approaches and outstanding challenges," PLoS Computational Biology, vol. 8, no. 2, Article ID e1002375, 2012.

D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.

P. A. Futreal, L. Coin, M. Marshall et al., "A census of human cancer genes," Nature Reviews Cancer, vol. 4, no. 3, pp. 177–183, 2004.

V. N. Babenko, M. K. Basu, F. A. Kondrashov, I. B. Rogozin, and E. V. Koonin, "Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis," BMC Cancer, vol. 6, article 36, 2006.

I. P. Gorlov, C. J. Logothetis, S. Fang, O. Y. Gorlova, and C. Amos, "Building a statistical model for predicting cancer genes," PLoS ONE, vol. 7, no. 11, Article ID e49175, 2012.